海馬硬化與癲癇_Journal of Epilepsy

Authors：

 高杰 ,  鄧艷春

第四軍醫大學西京醫院神經內科, 西安, 710032;

Corresponding?author：

鄧艷春, Email: yanchundeng@yahoo.com

Keywords：

海馬硬化; 顳葉癲癇; 研究進展

DOI：

10.7507/2096-0247.20160012

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

難治性癲癇的患者常常伴有海馬硬化, 是耐藥性癲癇的主要致病因素。海馬硬化在長期復雜的癲癇發作過程中逐漸形成, 兩者之間的作用關系一直是癲癇領域的研究熱點。現結合近年來國內外研究的新進展探討海馬硬化與癲癇之間的關系, 為顳葉癲癇的臨床診療提供新的思路

Citation： 高杰, 鄧艷春. 海馬硬化與癲癇. Journal of Epilepsy, 2016, 2(1): 64-66. doi: 10.7507/2096-0247.20160012 Copy

1.	Kasperaviciute D, Catarino CB, Matarin M, et al. Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A. Brain, 2013, 136(Pt10): 3140-3150.
2.	Zhang X, Bertaso F, Yoo JW, et al. Deletion of the potassium channel Kv12.2 causes hippocampal hyperexcitability and epilepsy. Nat Neurosci, 2010, 13(9): 1056-1058.
3.	Rowley S, Patel M. Mitochondrial involvement and oxidative stress in temporal lobe epilepsy. Free Radic Biol Med, 2013, 62(9) :121-131.
4.	Walker AI, Stevenson DE, Robinson J, et al. The toxicology and pharmacodynamics of dieldrin (HEOD): two-year oral exposures of rats and dogs. Toxicol Appl Pharmacol, 1969, 15(2): 345-373.
5.	朱長庚.神經-免疫-內分泌網絡與癲癇發病機理的關系.解剖學報, 2002, 33(3):321-324.
6.	Ong MS, Kohane IS, Cai T, et al. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol, 2014, 71(5): 569-574.
7.	Fang M, Xi ZQ, Wu Y, et al. A new hypothesis of drug refractory epilepsy: neural network hypothesis. Med Hypotheses, 2011, 76(6):871-876.
8.	路蟬伊, 劉立雄, 張云峰, 等.癲癇發病機制的研究進展.解放軍醫學院學報, 2014, 35(8): 876-880.
9.	Patel LS, Wenzel HJ, Schwartzkroin PA. Physiological and morphological characterization of dentate granule cells in the p35 knock-out mouse hippocampus: evidence for an epileptic circuit. J Neurosci, 2004, 24(41): 9005-9014.
10.	Heck N, Garwood J, Loeffler JP, et al. Differential upregulation of extracellular matrix molecules associated with the appearance of granule cell dispersion and mossy fiber sprouting during epileptogenesis in a murine model of temporal lobe epilepsy. Neuroscience, 2004, 129(2): 309-324.
11.	Dutra JR, Cortés EP, Vonsattel JP. Update on Hippocampal Sclerosis Curr Neurol Neurosci Rep. 2015, 15(10):67.
12.	Merlin LR, Bianchi R, Wong RK. Group I mGluR-dependent epileptogenesis. Epilepsia, 2010, 51(S5):16.
13.	Kandratavicius L, Rosa-Neto P, Monteiro MR, et al. Distinct increased metabotropic glutamate receptor type 5(mGluR5) in temporal lobe epilepsy with and without hippocampal sclerosis. Hippocampus, 2013, 23(12):1212-1230.
14.	Kang JQ, Barnes G. A common susceptibility factor of both autism and epilepsy :functional deficiency of GABA A receptors. Autism Dev Disord, 2013, 43(1):68-79.
15.	Frugier G, Coussen F, Giraud MF, et al. A gamma 2(R43Q) mutation, linked to epilepsy in humans, alters GABA A receptor assembly and modifies subunit composition on the cell surface. J Biol Chem, 2007, 282(6):3819-3828.
16.	Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int, 2006, 48(5): 394-403.
17.	Yernool D, Boudker O, Jin Y, et al. Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature, 2004, 431(7010): 811-818.
18.	O'Shea RD, Lau CL, Farso MC, et al. Effects of lipopolysaccharide on glial phenotype and activity of glutamate transporters: Evidence for delayed up-regulation and redistribution of GLT-1. Neurochem Int, 2006, 48(6-7): 604-610.
19.	Baer-Dubowska W, Majchrzak-Celi?ska A, Cichocki M. Pharmacoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep, 2011, 63(2): 293-304.
20.	James EJ, Gu J, Ramirez-Vizcarrondo CM, et al. Valproate-induced neurodevelopmental deficits in Xenopus laevis tadpoles. J Neurosci. 2015, 35(7): 3218-3229.
21.	Feng J, Cen J, Li J, et al. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail. Cell Adh Migr. 2015 Dec 2:0, Epub ahead of print.
22.	Mendoza-Sanchez R, Cotnoir-White D, Kulpa J, et al. Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids. Bioorg Med Chem, 2015, 11: S0968-0896(15)30130-9, Epub ahead of print.
23.	Sendrowski K, Sobaniec W. Hippocampus, hippocampal sclerosis and epilepsy. Pharmacol Rep, 2013, 65(3): 555-565.
24.	Chatzikonstantinou A. Epilepsy and the hippocampus. Front Neurol Neurosci, 2014, 34(16): 121-142.
25.	張立穎.卡馬西平聯合丙戊酸鈉治療顳葉癲癇.中國醫藥指南, 2014, 12(21): 127-128.
26.	張杰, 高晉健, 吳建兵, 等.術后早期停藥對顳葉癲癇患者遠期預后的影響.實用醫學雜志, 2014, 13: 2115-2117.
27.	Ladino LD, Hernández-Ronquillo L. Management of antiepileptic drugs following epilepsy surgery: a meta-analysis. Epilepsy Res, 2014, 108(4): 765-774.
28.	LM Selwa, SL Schmidt, BA Malow, et al. Long-term outcome of nonsurgical candidates with medically refractory localization-related epilepsy. Epilepsia, 2003, 44 (12): 1568-1572.
29.	AE Elsharkawy, R Thorbecke, A Ebner, et al. Determinants of quality of life in patients with refractory focal epilepsy who were not eligible for surgery or who rejected surgery. Epilepsy & Behavior, 2012, 24 (2): 249-255.

1. Kasperaviciute D, Catarino CB, Matarin M, et al. Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A. Brain, 2013, 136(Pt10): 3140-3150.
2. Zhang X, Bertaso F, Yoo JW, et al. Deletion of the potassium channel Kv12.2 causes hippocampal hyperexcitability and epilepsy. Nat Neurosci, 2010, 13(9): 1056-1058.
3. Rowley S, Patel M. Mitochondrial involvement and oxidative stress in temporal lobe epilepsy. Free Radic Biol Med, 2013, 62(9) :121-131.
4. Walker AI, Stevenson DE, Robinson J, et al. The toxicology and pharmacodynamics of dieldrin (HEOD): two-year oral exposures of rats and dogs. Toxicol Appl Pharmacol, 1969, 15(2): 345-373.
5. 朱長庚.神經-免疫-內分泌網絡與癲癇發病機理的關系.解剖學報, 2002, 33(3):321-324.
6. Ong MS, Kohane IS, Cai T, et al. Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol, 2014, 71(5): 569-574.
7. Fang M, Xi ZQ, Wu Y, et al. A new hypothesis of drug refractory epilepsy: neural network hypothesis. Med Hypotheses, 2011, 76(6):871-876.
8. 路蟬伊, 劉立雄, 張云峰, 等.癲癇發病機制的研究進展.解放軍醫學院學報, 2014, 35(8): 876-880.
9. Patel LS, Wenzel HJ, Schwartzkroin PA. Physiological and morphological characterization of dentate granule cells in the p35 knock-out mouse hippocampus: evidence for an epileptic circuit. J Neurosci, 2004, 24(41): 9005-9014.
10. Heck N, Garwood J, Loeffler JP, et al. Differential upregulation of extracellular matrix molecules associated with the appearance of granule cell dispersion and mossy fiber sprouting during epileptogenesis in a murine model of temporal lobe epilepsy. Neuroscience, 2004, 129(2): 309-324.
11. Dutra JR, Cortés EP, Vonsattel JP. Update on Hippocampal Sclerosis Curr Neurol Neurosci Rep. 2015, 15(10):67.
12. Merlin LR, Bianchi R, Wong RK. Group I mGluR-dependent epileptogenesis. Epilepsia, 2010, 51(S5):16.
13. Kandratavicius L, Rosa-Neto P, Monteiro MR, et al. Distinct increased metabotropic glutamate receptor type 5(mGluR5) in temporal lobe epilepsy with and without hippocampal sclerosis. Hippocampus, 2013, 23(12):1212-1230.
14. Kang JQ, Barnes G. A common susceptibility factor of both autism and epilepsy :functional deficiency of GABA A receptors. Autism Dev Disord, 2013, 43(1):68-79.
15. Frugier G, Coussen F, Giraud MF, et al. A gamma 2(R43Q) mutation, linked to epilepsy in humans, alters GABA A receptor assembly and modifies subunit composition on the cell surface. J Biol Chem, 2007, 282(6):3819-3828.
16. Yi JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury. Neurochem Int, 2006, 48(5): 394-403.
17. Yernool D, Boudker O, Jin Y, et al. Structure of a glutamate transporter homologue from Pyrococcus horikoshii. Nature, 2004, 431(7010): 811-818.
18. O'Shea RD, Lau CL, Farso MC, et al. Effects of lipopolysaccharide on glial phenotype and activity of glutamate transporters: Evidence for delayed up-regulation and redistribution of GLT-1. Neurochem Int, 2006, 48(6-7): 604-610.
19. Baer-Dubowska W, Majchrzak-Celi?ska A, Cichocki M. Pharmacoepigenetics: a new approach to predicting individual drug responses and targeting new drugs. Pharmacol Rep, 2011, 63(2): 293-304.
20. James EJ, Gu J, Ramirez-Vizcarrondo CM, et al. Valproate-induced neurodevelopmental deficits in Xenopus laevis tadpoles. J Neurosci. 2015, 35(7): 3218-3229.
21. Feng J, Cen J, Li J, et al. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail. Cell Adh Migr. 2015 Dec 2:0, Epub ahead of print.
22. Mendoza-Sanchez R, Cotnoir-White D, Kulpa J, et al. Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids. Bioorg Med Chem, 2015, 11: S0968-0896(15)30130-9, Epub ahead of print.
23. Sendrowski K, Sobaniec W. Hippocampus, hippocampal sclerosis and epilepsy. Pharmacol Rep, 2013, 65(3): 555-565.
24. Chatzikonstantinou A. Epilepsy and the hippocampus. Front Neurol Neurosci, 2014, 34(16): 121-142.
25. 張立穎.卡馬西平聯合丙戊酸鈉治療顳葉癲癇.中國醫藥指南, 2014, 12(21): 127-128.
26. 張杰, 高晉健, 吳建兵, 等.術后早期停藥對顳葉癲癇患者遠期預后的影響.實用醫學雜志, 2014, 13: 2115-2117.
27. Ladino LD, Hernández-Ronquillo L. Management of antiepileptic drugs following epilepsy surgery: a meta-analysis. Epilepsy Res, 2014, 108(4): 765-774.
28. LM Selwa, SL Schmidt, BA Malow, et al. Long-term outcome of nonsurgical candidates with medically refractory localization-related epilepsy. Epilepsia, 2003, 44 (12): 1568-1572.
29. AE Elsharkawy, R Thorbecke, A Ebner, et al. Determinants of quality of life in patients with refractory focal epilepsy who were not eligible for surgery or who rejected surgery. Epilepsy & Behavior, 2012, 24 (2): 249-255.

Previous Article
特發性全面性癲癇的神經影像研究進展
Next Article
抗癲癇藥物與自殺的關系——國際抗癲癇聯盟治療方法委員會手術治療協作組報告

Journal of Epilepsy

海馬硬化與癲癇

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content